Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study.

To evaluate the effect of lurasidone on a new, patient Life Engagement scale in schizophrenia. This post-hoc analysis included participants (ages 18 to 74) diagnosed with schizophrenia who were randomized to lurasidone (40 mg/day) or placebo in a 6-week double-blind efficacy study and those who continued in a subsequent 12-week open-label extension study during which patients received either 40 or 80/mg day lurasidone (flexibly dosed). Change in life engagement was measured using the Positive and Negative Syndrome Scale (PANSS) 11-item Life Engagement subscale score, and individual subscale items, at week 6 during the double-blind phase and extension phase week 12 during the open-label extension phase. Analysis focused on 478 subjects randomized to lurasidone or placebo during the 6-week trial, and 146 who received lurasidone during the extension phase. During the 6-week trial, there was a significantly greater change on the PANSS This post-hoc analysis suggests that lurasidone may improve life engagement in patients with schizophrenia, a meaningful outcome from patients' perspective. Further studies are needed to confirm this effect. Trial registration: EudraCT Numbers: 2016-000060-42; 2016-000061-23.

Informations de copyright

© 2024 Maruyama et al.

Déclaration de conflit d'intérêts

I Miura reports personal fees from Sumitomo Pharma Co., Ltd., Eisai, Janssen, Meiji Seika Pharma, MSD, Otsuka, Takeda, Tanabe-Mitsubishi, Towa, Yoshitomi, Viatris, outside the submitted work. H Maruyama, F Sano, R Sakaguchi, and K Okamoto are full-time employees of Sumitomo Pharma Co., Ltd. The authors report no other conflicts of interest in this work.